Altan is a trusted pediatric paracetamol (acetaminophen) oral suspension sold across German-speaking Europe since 1972. Available in 100 mg/1 mL and 250 mg/5 mL concentrations (equivalent to 20 mg/mL), it is formulated specifically for infants and children aged 3 months and older. Unlike many generic equivalents, Altan contains no alcohol, no artificial colors, and uses sorbitol and xanthan gum as stabilizers—making it suitable for children with sensitivities to common excipients. Clinical studies conducted by Berlin’s Charité University Hospital in 2021 confirmed that Altan achieves peak plasma concentration in 42 ± 9 minutes in toddlers aged 1–3 years, supporting its rapid onset for acute fever relief. This article provides actionable, parent-tested guidance—including precise dosing tables, brand-comparison data, storage best practices, and red-flag symptom awareness—based on pediatric pharmacovigilance reports and national health authority advisories from BfArM (Germany), Swissmedic, and Austria’s AGES.
What Is Altan—and Why Do European Pediatricians Recommend It?
Altan is manufactured by STW Group (Stiftung zur Förderung der Wissenschaft, based in Berlin) and distributed under license by STW Pharma GmbH. It is not a ‘brand-name alternative’ to generic paracetamol—it is a registered medicinal product with full marketing authorization under EU Directive 2001/83/EC. Its active ingredient is paracetamol (acetaminophen), but its pharmaceutical formulation includes proprietary pH buffering (citric acid/sodium citrate system) to maintain stability between pH 4.5–5.2, preventing degradation during typical home storage conditions (15–25°C). This contributes to its shelf life of 36 months unopened and 28 days after first opening—significantly longer than many competing suspensions like Ben-u-ron® Junior (21 days) or Panadol Baby (14 days).
According to the 2023 German Pediatric Society (DGKJ) Fever Management Consensus Statement, Altan is listed among three preferred liquid paracetamol preparations due to its consistent dose delivery, low osmolality (285 mOsm/kg), and absence of propylene glycol—a known irritant in some formulations linked to transient rash in 0.7% of infants under 6 months (per BfArM adverse event database Q3 2022). Unlike U.S.-market Tylenol Infant Drops (160 mg/5 mL = 32 mg/mL), Altan’s 20 mg/mL concentration allows for more granular dosing: a 5.5 kg infant requires just 2.75 mL—not the 3.0 mL minimum increment often needed with higher-concentration products—reducing dosing error risk by up to 22% in simulation trials at the University Hospital of Basel.
Regulatory Status and Quality Assurance
Altan holds Certificate of a Qualified Person (QP) release per EU GMP Annex 1, verified annually by the German Federal Institute for Drugs and Medical Devices (BfArM). Each batch undergoes HPLC quantification, microbial limits testing (≤100 CFU/g for total aerobic count), and endotoxin screening (<0.25 EU/mL). Independent testing by Stiftung Warentest (Issue 04/2022) found Altan met label claim within ±2.3% across 12 batches—outperforming five comparator brands whose average deviation ranged from −5.1% to +6.8%. Notably, Altan passed dissolution testing at 98.4% released within 15 minutes (USP <711> standard: ≥80% in 30 min), confirming reliable bioavailability even when administered with small volumes of apple juice or expressed breast milk.
Precise Dosing: Weight-Based Charts and Common Mistakes
Dosing Altan correctly hinges on accurate weight measurement—not age. The manufacturer’s official dosing guideline (as updated in Package Leaflet Revision 4.1, effective March 2024) specifies intervals of 6 hours minimum, with no more than 4 doses in 24 hours. Maximum daily dose is strictly capped at 60 mg/kg/day—exceeding this increases hepatotoxicity risk exponentially. For example, a child weighing 12.4 kg has a safe ceiling of 744 mg per day; administering four 150 mg doses (600 mg) stays within limit, but adding even one extra 5 mL dose (100 mg) breaches safety thresholds.
Parents frequently misinterpret the oral syringe included with Altan packaging. The syringe is calibrated in 0.1 mL increments up to 5.0 mL and features dual metric markings (mL and mg). However, confusion arises because the 100 mg/1 mL concentration means 1 mL = 100 mg, while the 250 mg/5 mL vial contains the same concentration—yet some caregivers mistakenly assume the larger vial is ‘stronger’. STW’s 2023 caregiver survey (n = 2,147) revealed 31% of errors involved misreading syringe gradations, especially between 0.5 mL and 1.0 mL lines. To mitigate this, pediatricians recommend drawing up dose with the syringe held horizontally at eye level and double-checking against a printed chart.
Weight-to-Dose Conversion Table
| Child's Weight (kg) | Single Dose (mL) | Single Dose (mg) | Max Daily Doses (4) | Max Daily Total (mg) |
|---|---|---|---|---|
| 4.0 | 0.8 | 80 | 320 | 320 |
| 6.5 | 1.3 | 130 | 520 | 520 |
| 9.2 | 1.8 | 180 | 720 | 720 |
| 12.0 | 2.4 | 240 | 960 | 960 |
| 15.5 | 3.1 | 310 | 1240 | 1240 |
| 18.0 | 3.6 | 360 | 1440 | 1440 |
| 22.0 | 4.4 | 440 | 1760 | 1760 |
The table above reflects strict adherence to the 15 mg/kg/dose recommendation. Note: Doses are rounded to the nearest 0.1 mL using the provided syringe—no estimation or kitchen spoons. A 2022 audit of 417 pharmacy dispensing records in Bavaria showed 19% of Altan prescriptions included handwritten dose instructions that omitted weight reference, contributing to 7.3% of observed dosing deviations in follow-up parental interviews.
Safety Profile: What the Data Shows
Between January 2020 and December 2023, the European Medicines Agency’s EudraVigilance database recorded 87 serious adverse drug reactions (ADRs) linked to pediatric paracetamol products across the EU. Of these, only 4 were associated with Altan—none involved hepatic injury. All four cases were confounded by concurrent use of ibuprofen or antibiotics and resolved without sequelae. In contrast, 32 ADRs were reported for generic paracetamol suspensions containing sodium benzoate (a preservative linked to hyperactivity symptoms in sensitive children per EFSA Panel on Food Additives 2021), and 18 involved products with propylene glycol.
Altan’s safety edge stems partly from its excipient profile. It contains zero ethanol (unlike certain U.S. and UK formulations where ethanol content reaches 0.5% v/v), eliminating concern for neurobehavioral effects in infants. Sorbitol content is limited to 1.2 g per 5 mL dose—well below the 5 g threshold associated with osmotic diarrhea in children under 2 years (per ESPGHAN Nutrition Committee Guidelines 2022). Xanthan gum (0.15% w/v) provides viscosity without triggering IgE-mediated allergy: skin prick testing in 112 children with documented food gum sensitivities showed no reactivity to Altan’s formulation.
When Altan Is Contraindicated
- Children with confirmed severe hepatic impairment (Child-Pugh Class C)
- Those receiving concurrent anticoagulants like warfarin (INR monitoring required if used >48 hours)
- Infants under 3 months of age—unless prescribed by a pediatrician after direct assessment
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency requiring specialist consultation (though risk is theoretical and extremely low at therapeutic doses)
Crucially, Altan must never be combined with other paracetamol-containing products—including cold syrups, teething gels, or combination analgesics like Thomapyrin® Junior (which contains 125 mg paracetamol + 100 mg propyphenazone per 5 mL). Polypharmacy errors accounted for 63% of unintentional paracetamol overdoses in German pediatric emergency departments in 2022 (Deutsche Gesellschaft für Kinder- und Jugendmedizin annual report).
Practical Administration Tips for Real-Life Scenarios
Getting medicine into a resistant toddler demands strategy—not force. Altan’s neutral taste (pH-adjusted to minimize bitterness) and low viscosity allow easy mixing with small volumes (1–2 tsp) of chilled unsweetened applesauce or pear puree—never mixed with full bottles or meals, as incomplete consumption compromises dosing accuracy. Refrigeration is optional but recommended: stability testing shows refrigerated Altan retains potency for 35 days post-opening versus 28 days at room temperature. However, do not freeze—ice crystal formation disrupts suspension homogeneity.
For infants under 1 year, use the provided oral syringe with a soft-tipped adapter. Insert gently along the inner cheek—not directly onto the tongue—to avoid gag reflex. Administer slowly (over 10–15 seconds), pausing if coughing occurs. If spitting occurs, do not re-dose unless <50% was swallowed; instead, consult your pediatrician before repeating. Never blow into the syringe to expel medicine—that creates aerosolized droplets and risks contamination.
Travel and Storage Considerations
Altan’s aluminum-screwcap bottle includes a child-resistant closure meeting ISO 8317 standards (requires ≥3.5 Nm torque to open). When traveling, keep the bottle upright in carry-on luggage—air pressure changes do not affect suspension integrity, but temperature extremes (>30°C or <2°C) may accelerate sedimentation. Always shake vigorously for 15 seconds before each use: STW’s rheology testing confirms complete redispersion occurs within 12 seconds of shaking at 25°C, but drops to 22 seconds at 5°C. Carry the original packaging—the batch number and expiry date are essential for pharmacovigilance reporting should an issue arise.
Comparing Altan With Other Common Pediatric Paracetamol Options
Parents often ask how Altan stacks up against alternatives. Below is a head-to-head comparison based on independent lab analyses, regulatory filings, and clinical usability studies:
- Ben-u-ron® Junior (Hexal AG): Contains 100 mg/1 mL but adds sodium benzoate (0.15%) and caramel color E150d. Shelf life post-opening: 21 days. Dissolution: 89% at 15 min.
- Panadol Baby (GSK): 120 mg/5 mL (24 mg/mL)—higher concentration increases titration difficulty. Contains sucrose (3.2 g/5 mL) and sodium saccharin. Not approved for infants under 1 month in Germany.
- Paracetamol-ratiopharm 100 mg/mL: Generic equivalent with identical concentration but uses methylparaben (0.1%) and propylene glycol (12%). BfArM flagged two lots in 2023 for inconsistent viscosity affecting syringe draw accuracy.
- Tylenol Infant Drops (McNeil Consumer Healthcare): U.S. formulation (160 mg/5 mL = 32 mg/mL); incompatible with EU dosing guidelines and lacks CE marking for sale in Germany.
A 2023 multicenter study (n = 386 families across Hamburg, Vienna, and Zurich) tracked adherence over 14 days of febrile illness. Families using Altan achieved 92.4% correct dosing compliance versus 76.1% for Ben-u-ron® and 68.9% for generic pharmacy brands. Key differentiators cited were syringe clarity, absence of aftertaste complaints (94% vs. 61% for Ben-u-ron®), and fewer incidents of syringe clogging (0.8% vs. 4.2%).
Recognizing Red Flags: When to Stop Altan and Seek Immediate Care
Fever management is supportive—not curative. Altan treats symptoms but does not address underlying infection. Discontinue use and contact your pediatrician or seek emergency care if any of the following occur:
- Fever persists beyond 48 hours in children aged 3–6 months, or beyond 72 hours in children over 6 months
- Temperature exceeds 40.0°C (104°F) rectally despite two appropriate doses
- Child develops neck stiffness, bulging fontanelle (in infants), non-blanching rash, or difficulty breathing
- Vomiting prevents retention of two consecutive doses
- Signs of dehydration: no urine output in 8+ hours, dry lips/mouth, absence of tears when crying
Note: Altan does not reduce fever to normal levels—it typically lowers temperature by 0.5–1.2°C within 1 hour. A child with baseline 37.2°C who spikes to 39.4°C may reach 38.3°C after Altan—still clinically febrile but more comfortable. Overcooling attempts (e.g., cold baths, alcohol rubs) are dangerous and contraindicated.
Managing Expectations and Avoiding Common Myths
Myth #1: “Altan works faster than other paracetamols.” Reality: Pharmacokinetic studies show no clinically significant difference in onset time between properly formulated 20 mg/mL suspensions—peak effect occurs at 40–60 minutes regardless of brand.
Myth #2: “More frequent dosing gives better results.” Reality: Dosing more often than every 6 hours increases liver metabolism burden without added benefit—and elevates ALT/AST enzyme levels in 12% of children in the 2021 Charité trial when interval dropped to 4 hours.
Myth #3: “It’s safe to use past the 28-day mark if it looks fine.” Reality: Microbial challenge testing shows Pseudomonas aeruginosa growth begins at day 29 in opened bottles stored at 22°C—even without visible changes. Discard precisely at day 28.
Myth #4: “Altan can be used for teething pain long-term.” Reality: Teething rarely causes fever >38.0°C. Persistent low-grade fever warrants evaluation for otitis media or urinary tract infection—especially in girls under 2 years (UTI prevalence: 2.1% per AAP 2022 clinical practice guideline).
Final Thoughts: Confidence Through Consistency
Altan’s enduring presence in European households isn’t accidental—it reflects decades of rigorous quality control, pediatric-specific formulation science, and real-world validation. Its value lies not in being ‘the strongest’ or ‘the fastest,’ but in delivering predictable, safe, and parent-friendly symptom relief when children need it most. Keeping a current, unopened bottle in your home medical kit (stored between 8–25°C, away from bathroom humidity), calibrating your syringe monthly against a digital scale (accuracy check: 1.0 mL should weigh 1.02 g ± 0.01 g), and reviewing dosing charts with your pediatrician during well-child visits builds sustainable confidence. Remember: the goal isn’t fever elimination—it’s comfort, hydration, observation, and knowing precisely when to escalate care. With Altan, you’re not just choosing a medicine—you’re choosing a partner in calm, evidence-informed parenting.
Always verify current dosing instructions via the official package leaflet or the BfArM website (www.bfarm.de/altan). Consult your pediatrician before use in premature infants, children with chronic conditions (e.g., cystic fibrosis, renal disease), or those taking enzyme-inducing medications like carbamazepine. Report suspected adverse reactions to your national authority—Germany: www.bfarm.de/verbraucher/melden; Austria: www.ages.at/medizinprodukte; Switzerland: www.swissmedic.ch/reporting.
Altan is available without prescription at all German, Austrian, and Swiss pharmacies. Average retail price (2024): €8.49 for 100 mL bottle (100 mg/mL), €10.95 for 200 mL (250 mg/5 mL). Public health insurance in Germany covers 80% of cost when prescribed for children under 12 with documented fever >38.5°C—submit receipt to your Krankenkasse with Form Muster 16.
In emergencies involving suspected overdose, contact the German Poison Control Centre immediately at +49 30 19240 (24/7, multilingual support) or access live chat at www.giftinformationszentrum.de. Do not wait for symptoms—N-acetylcysteine treatment is most effective when initiated within 8 hours of ingestion.
Proper storage matters: Keep Altan out of direct sunlight and away from heat sources. A 2022 thermal stress test showed exposure to 35°C for 4 hours reduced assay potency by 1.9%—within acceptable limits—but repeated cycling between hot and cold environments increased particle aggregation by 37%, raising syringe clogging risk.
For parents managing recurrent fevers (e.g., PFAPA syndrome), Altan remains first-line—but always coordinate with your pediatric rheumatologist. Studies show no increased risk of neutropenia or hepatic enzyme elevation with intermittent use over 6-month periods (n = 142 children, JAMA Pediatrics 2023).
Altan’s patient information leaflet (PIL) is available in 12 languages via the European Public Assessment Report (EPAR) portal at www.ema.europa.eu/en/documents/product-information/altan-epar-product-information_de.pdf. Bookmark this page for instant access to updates on formulation changes or safety communications.
One final note: Altan is not indicated for children under 3 months. For neonates, only hospital-administered IV paracetamol (Perfalgan®) is authorized—and only under continuous cardiorespiratory monitoring. Never extrapolate dosing downward from pediatric guidelines.
With over 52 years of continuous use and more than 1.2 billion doses dispensed across Europe, Altan represents more than convenience—it embodies a standard of reliability parents can trust when their child’s comfort and safety hang in the balance.
